Andrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) Stock

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James purchased 97,561 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was acquired at an average price of $2.05 per share, for a total transaction of $200,000.05. Following the completion of the purchase, the chief financial officer now directly owns 151,231 shares of the company’s stock, valued at $310,023.55. This represents a 181.78 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

OncoCyte Trading Up 14.5 %

Shares of OncoCyte stock opened at $2.37 on Wednesday. OncoCyte Co. has a 12-month low of $1.92 and a 12-month high of $3.48. The firm’s 50-day moving average price is $2.20 and its two-hundred day moving average price is $2.71.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same quarter last year, the firm earned ($0.57) EPS. Equities research analysts anticipate that OncoCyte Co. will post -2.57 EPS for the current year.

Analyst Upgrades and Downgrades

OCX has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Wednesday, November 13th. StockNews.com initiated coverage on shares of OncoCyte in a research note on Monday, January 13th. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC raised its stake in OncoCyte Co. (NASDAQ:OCX) by 12.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 103,980 shares of the company’s stock after acquiring an additional 11,289 shares during the quarter. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. 55.35% of the stock is currently owned by institutional investors and hedge funds.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.